The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: ILD with a granulomatous component (see also Im)
Publications
Sirolimus-induced pneumonitis following liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2007;13(6):853-6
Pulmonary toxicity associated with sirolimus treatment in kidney transplantation.
Transplantation proceedings. 2006;38(8):2438-40
Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.
Chest. 2006;129(6):1718-21
Patterns of pulmonary complications associated with sirolimus.
Respiration; international review of thoracic diseases. 2006;73(3):367-74
Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation.
Journal of pediatric gastroenterology and nutrition. 2003;37(1):91-4
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
Transplantation. 2001;72(5):787-90